EFFECTS OF SELINEXOR ON PREVIOUSLY TREATED MULTIPLE MYELOMA (MM) WITH RAS-MUTATIONS
Published date:
05/12/2021
Excerpt:
In BOSTON, pts with RASmut MM treated with XVd had significantly longer progression-free survival (PFS) than those treated with Vd (median [med]=12.9 vs 6.7 months [mo], hazard ratio [HR]=0.48 [95% CI 0.24-0.97], p=0.039).